Loading…
Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah’s Witness patients: A review of reported cases
Devout members of the Jehovah’s Witness faith flatly refuse transfusions of white blood cells, red blood cells, platelets, and plasma. The latter agent is a mainstay in the treatment of thrombotic thrombocytopenic purpura (TTP). Alternative treatment options for Jehovah’s Witness patients are needed...
Saved in:
| Published in: | Transfusion and apheresis science 2023-08, Vol.62 (4), p.103706-103706, Article 103706 |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c365t-d20d10b2525203d59ee38e9698018ca6a9a325b667c03b27c7147937369a2293 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c365t-d20d10b2525203d59ee38e9698018ca6a9a325b667c03b27c7147937369a2293 |
| container_end_page | 103706 |
| container_issue | 4 |
| container_start_page | 103706 |
| container_title | Transfusion and apheresis science |
| container_volume | 62 |
| creator | Tran, Minh-Ha |
| description | Devout members of the Jehovah’s Witness faith flatly refuse transfusions of white blood cells, red blood cells, platelets, and plasma. The latter agent is a mainstay in the treatment of thrombotic thrombocytopenic purpura (TTP). Alternative treatment options for Jehovah’s Witness patients are needed and reviewed herein.
Cases of TTP treatment among Jehovah’s Witnesses were obtained from the published literature. Key baseline and clinical data were extracted and summarized.
A total of 13 reports spanning a 23-year period and 15 TTP episodes were identified. Median (IQR) age was 45.5 (29.0–57.5) and 12/13 (93%) patients were female. Neurologic symptoms were present in 7/15 (47%) episodes at presentation. Disease confirmation with ADAMTS13 testing was present in 11/15 (73%) of episodes. Corticosteroids and rituximab were employed in 13/15 (87%) and 12/15 (80%) of cases, respectively, with apheresis-based therapy employed in 9/15 (60%) episodes. For eligible cases, caplacizumab was used in 4/5 (80%) episodes; average time to platelet response was shortest in these cases. Sources of exogenous ADAMTS13 accepted by patients in this series included cryo-poor plasma, FVIII concentrate, and cryoprecipitate. Conclusions: Successful management of TTP within the boundaries of the Jehovah’s Witness faith is possible. |
| doi_str_mv | 10.1016/j.transci.2023.103706 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2792902181</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473050223000800</els_id><sourcerecordid>2792902181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-d20d10b2525203d59ee38e9698018ca6a9a325b667c03b27c7147937369a2293</originalsourceid><addsrcrecordid>eNqFUctuFDEQtBARCYFPAPnIZRY_MvaYC4oiQoIicVmJo9Xj6c16tWMPtidRbtz4hvweXxKvdsk1siWX2tXV6ipCPnC24Iyrz5tFSRCy8wvBhKw1qZl6RU54p7uGq06-rvhMy4a1TByTtzlvGOOaG_WGHEtlDOvM2Qn5u1xjggnn4h0d4wBbXzxm6gMt6xTHPu4-DtA9lDhhqIVpTvUCHSHALY4YCoUxhlv6A9fxDtb__jxm-suXgDnTCapkKPkLPacJ7zze07iqaIqp4EAdZMzvyNEKthnfH95Tsrz8try4am5-fr--OL9pnFRtaQbBBs560dbD5NAaRNmhUaZjvHOgwIAUba-Udkz2QjtdPTBS14VBCCNPyae97JTi7xlzsaPPDrdbCBjnbIU2wjDBO16p7Z7qUsw54cpOyY-QHixndheB3dhDBHYXgd1HUPs-HkbM_YjDc9d_zyvh656Adc_qRrJVAoPDwSd0xQ7RvzDiCTLTnXM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2792902181</pqid></control><display><type>article</type><title>Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah’s Witness patients: A review of reported cases</title><source>ScienceDirect Freedom Collection</source><creator>Tran, Minh-Ha</creator><creatorcontrib>Tran, Minh-Ha</creatorcontrib><description>Devout members of the Jehovah’s Witness faith flatly refuse transfusions of white blood cells, red blood cells, platelets, and plasma. The latter agent is a mainstay in the treatment of thrombotic thrombocytopenic purpura (TTP). Alternative treatment options for Jehovah’s Witness patients are needed and reviewed herein.
Cases of TTP treatment among Jehovah’s Witnesses were obtained from the published literature. Key baseline and clinical data were extracted and summarized.
A total of 13 reports spanning a 23-year period and 15 TTP episodes were identified. Median (IQR) age was 45.5 (29.0–57.5) and 12/13 (93%) patients were female. Neurologic symptoms were present in 7/15 (47%) episodes at presentation. Disease confirmation with ADAMTS13 testing was present in 11/15 (73%) of episodes. Corticosteroids and rituximab were employed in 13/15 (87%) and 12/15 (80%) of cases, respectively, with apheresis-based therapy employed in 9/15 (60%) episodes. For eligible cases, caplacizumab was used in 4/5 (80%) episodes; average time to platelet response was shortest in these cases. Sources of exogenous ADAMTS13 accepted by patients in this series included cryo-poor plasma, FVIII concentrate, and cryoprecipitate. Conclusions: Successful management of TTP within the boundaries of the Jehovah’s Witness faith is possible.</description><identifier>ISSN: 1473-0502</identifier><identifier>EISSN: 1878-1683</identifier><identifier>DOI: 10.1016/j.transci.2023.103706</identifier><identifier>PMID: 36990894</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Caplacizumab ; Jehovah’s Witness ; Koate ; Rituximab ; Thrombotic Thrombocytopenic Purpura ; TTP</subject><ispartof>Transfusion and apheresis science, 2023-08, Vol.62 (4), p.103706-103706, Article 103706</ispartof><rights>2023 Elsevier Ltd</rights><rights>Copyright © 2023 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-d20d10b2525203d59ee38e9698018ca6a9a325b667c03b27c7147937369a2293</citedby><cites>FETCH-LOGICAL-c365t-d20d10b2525203d59ee38e9698018ca6a9a325b667c03b27c7147937369a2293</cites><orcidid>0000-0002-9974-5277</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36990894$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tran, Minh-Ha</creatorcontrib><title>Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah’s Witness patients: A review of reported cases</title><title>Transfusion and apheresis science</title><addtitle>Transfus Apher Sci</addtitle><description>Devout members of the Jehovah’s Witness faith flatly refuse transfusions of white blood cells, red blood cells, platelets, and plasma. The latter agent is a mainstay in the treatment of thrombotic thrombocytopenic purpura (TTP). Alternative treatment options for Jehovah’s Witness patients are needed and reviewed herein.
Cases of TTP treatment among Jehovah’s Witnesses were obtained from the published literature. Key baseline and clinical data were extracted and summarized.
A total of 13 reports spanning a 23-year period and 15 TTP episodes were identified. Median (IQR) age was 45.5 (29.0–57.5) and 12/13 (93%) patients were female. Neurologic symptoms were present in 7/15 (47%) episodes at presentation. Disease confirmation with ADAMTS13 testing was present in 11/15 (73%) of episodes. Corticosteroids and rituximab were employed in 13/15 (87%) and 12/15 (80%) of cases, respectively, with apheresis-based therapy employed in 9/15 (60%) episodes. For eligible cases, caplacizumab was used in 4/5 (80%) episodes; average time to platelet response was shortest in these cases. Sources of exogenous ADAMTS13 accepted by patients in this series included cryo-poor plasma, FVIII concentrate, and cryoprecipitate. Conclusions: Successful management of TTP within the boundaries of the Jehovah’s Witness faith is possible.</description><subject>Caplacizumab</subject><subject>Jehovah’s Witness</subject><subject>Koate</subject><subject>Rituximab</subject><subject>Thrombotic Thrombocytopenic Purpura</subject><subject>TTP</subject><issn>1473-0502</issn><issn>1878-1683</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFUctuFDEQtBARCYFPAPnIZRY_MvaYC4oiQoIicVmJo9Xj6c16tWMPtidRbtz4hvweXxKvdsk1siWX2tXV6ipCPnC24Iyrz5tFSRCy8wvBhKw1qZl6RU54p7uGq06-rvhMy4a1TByTtzlvGOOaG_WGHEtlDOvM2Qn5u1xjggnn4h0d4wBbXzxm6gMt6xTHPu4-DtA9lDhhqIVpTvUCHSHALY4YCoUxhlv6A9fxDtb__jxm-suXgDnTCapkKPkLPacJ7zze07iqaIqp4EAdZMzvyNEKthnfH95Tsrz8try4am5-fr--OL9pnFRtaQbBBs560dbD5NAaRNmhUaZjvHOgwIAUba-Udkz2QjtdPTBS14VBCCNPyae97JTi7xlzsaPPDrdbCBjnbIU2wjDBO16p7Z7qUsw54cpOyY-QHixndheB3dhDBHYXgd1HUPs-HkbM_YjDc9d_zyvh656Adc_qRrJVAoPDwSd0xQ7RvzDiCTLTnXM</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Tran, Minh-Ha</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9974-5277</orcidid></search><sort><creationdate>20230801</creationdate><title>Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah’s Witness patients: A review of reported cases</title><author>Tran, Minh-Ha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-d20d10b2525203d59ee38e9698018ca6a9a325b667c03b27c7147937369a2293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Caplacizumab</topic><topic>Jehovah’s Witness</topic><topic>Koate</topic><topic>Rituximab</topic><topic>Thrombotic Thrombocytopenic Purpura</topic><topic>TTP</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tran, Minh-Ha</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion and apheresis science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tran, Minh-Ha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah’s Witness patients: A review of reported cases</atitle><jtitle>Transfusion and apheresis science</jtitle><addtitle>Transfus Apher Sci</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>62</volume><issue>4</issue><spage>103706</spage><epage>103706</epage><pages>103706-103706</pages><artnum>103706</artnum><issn>1473-0502</issn><eissn>1878-1683</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><abstract>Devout members of the Jehovah’s Witness faith flatly refuse transfusions of white blood cells, red blood cells, platelets, and plasma. The latter agent is a mainstay in the treatment of thrombotic thrombocytopenic purpura (TTP). Alternative treatment options for Jehovah’s Witness patients are needed and reviewed herein.
Cases of TTP treatment among Jehovah’s Witnesses were obtained from the published literature. Key baseline and clinical data were extracted and summarized.
A total of 13 reports spanning a 23-year period and 15 TTP episodes were identified. Median (IQR) age was 45.5 (29.0–57.5) and 12/13 (93%) patients were female. Neurologic symptoms were present in 7/15 (47%) episodes at presentation. Disease confirmation with ADAMTS13 testing was present in 11/15 (73%) of episodes. Corticosteroids and rituximab were employed in 13/15 (87%) and 12/15 (80%) of cases, respectively, with apheresis-based therapy employed in 9/15 (60%) episodes. For eligible cases, caplacizumab was used in 4/5 (80%) episodes; average time to platelet response was shortest in these cases. Sources of exogenous ADAMTS13 accepted by patients in this series included cryo-poor plasma, FVIII concentrate, and cryoprecipitate. Conclusions: Successful management of TTP within the boundaries of the Jehovah’s Witness faith is possible.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36990894</pmid><doi>10.1016/j.transci.2023.103706</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-9974-5277</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-0502 |
| ispartof | Transfusion and apheresis science, 2023-08, Vol.62 (4), p.103706-103706, Article 103706 |
| issn | 1473-0502 1878-1683 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2792902181 |
| source | ScienceDirect Freedom Collection |
| subjects | Caplacizumab Jehovah’s Witness Koate Rituximab Thrombotic Thrombocytopenic Purpura TTP |
| title | Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah’s Witness patients: A review of reported cases |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T22%3A38%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20modalities%20in%20thrombotic%20thrombocytopenic%20purpura%20management%20among%20Jehovah%E2%80%99s%20Witness%20patients:%20A%20review%20of%20reported%20cases&rft.jtitle=Transfusion%20and%20apheresis%20science&rft.au=Tran,%20Minh-Ha&rft.date=2023-08-01&rft.volume=62&rft.issue=4&rft.spage=103706&rft.epage=103706&rft.pages=103706-103706&rft.artnum=103706&rft.issn=1473-0502&rft.eissn=1878-1683&rft_id=info:doi/10.1016/j.transci.2023.103706&rft_dat=%3Cproquest_cross%3E2792902181%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c365t-d20d10b2525203d59ee38e9698018ca6a9a325b667c03b27c7147937369a2293%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2792902181&rft_id=info:pmid/36990894&rfr_iscdi=true |